Denis LUCQUIN

Denis Lucquin is a Managing Partner and Chairman of Sofinnova Partners. In life sciences, he specializes in industrial biotechnology investments. He joined Sofinnova in 1991. Denis began his career in academic research. For five years, he was in charge of the technology transfer department at the Institut National de la Recherche Agronomique (INRA), France’s agricultural research institute. In 1989, he joined the venture capital industry as director of investments at Innolion (Crédit Lyonnais). He carried out many investments in Europe such as Nicox, Oxford Glycosciences, Oxford Molecular, PPL Therapeutics, Conjuchem, Exonhit, IDM, Innate Pharma, and Ablynx (all of which successfully went public) as well as Novexel (sold to Astrazeneca), Crop Design, Cerenis, and Noxxon. He recently invested in BioAmber and Green Biologics, developers of bio-sourced molecules for the chemical industry, and in Avantium, a renewable chemicals company developing biobased plastic bottles for food and beverage. He acts or has acted as a board member for all these companies. Denis is also a founder of the France Biotech Association. He is a graduate in engineering from Ecole Polytechnique and Ecole du Génie Rural des Eaux et Forêts. He has a degree in Innovation Management from the Université de Paris-Dauphine.